Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma
Drug: Atezolizumab
338 locations incl. Birmingham
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT01810913·Phase 2, Phase 3·Recruiting